CSE Biotech
July 1, 2026
Three CSE-Listed Biotechs With Active Phase 2 Trials That Analysts Are Watching
The CSE is home to a growing cohort of early-stage biotechs. Three of them have Phase 2 programs that have quietly advanced and could attract significant attention if upcoming data supports the…
Read full story →
